NeuroVive: Interim Report 1 Jan. 2015 to 30 Sep. 2015

Focus forward on R&D
Third Quarter (1 July 2015 – 30 Sept. 2015)

  · Net revenues were SEK 0 (7,152,000) and other operating income was SEK
74,000 (2,000).
  · Loss before tax was SEK 53,948,000 (3,761,000). (For further information see
page 6.)
  · Impaired value for the CIRCUS-study was SEK 28,135,000 (0)
  · Earnings per share* were SEK -1.75 (-0.18).
  · Diluted earnings per share** were SEK -1.75 (-0.18).

Nine Months (1 Jan. 2015 – 30 Sept. 2015)

  · Net revenues were SEK 2,502,000 (7,152,000) and other operating income was
SEK 499,000 (1,173,000).
  · Loss before tax was SEK 83,435,000 (-27,328,000). (For further information
see page 6.)
  · Impaired value for the CIRCUS-study was SEK28,135,000 (0)
  ·  Earnings per share* were SEK -2.78 (-1,07).
  · Diluted earnings per share** were SEK -2.78 (-1,07).

* Profit/loss for the period divided by the average number of shares before
dilution at the end of the period.
**Profit/loss for the period divided by the average number of shares after
dilution at the end of the period.

Business highlights in the third quarter of 2015

  · NeuroVive refocused CicloMulsion development and discontinued acute
myocardial infarction indication. This decision follows the data from the
investigator-initiated Phase III CIRCUS study of CicloMulsion® in patients with
a specific type of heart attack known as ST-segment elevation myocardial
infarction (STEMI) showed that CicloMulsion® had no therapeutic effect on AMI
patients undergoing PCI (percutaneous coronary intervention).

  · NeuroVive announced the departure of CEO, Mikael Brönnegård, and Jan
Nilsson, COO, will head up the company in the role of interim CEO in the period
until a new CEO is appointed by the Board of Directors. The recruitment process
to find a successor has begun.

Events post balance sheet

  · NeuroVive aims to find path forward in antiviral development following
discontinuation of OCB-030 preclinical program by Arbutus, formerly OnCore
Biopharma, who have decided to discontinue development of OCB-030 (NVP018) so
the company can focus its resources on other agents that directly target HBV.
NeuroVive believes that the compound still has future potential based on the
independent evidence that supports its application in this area.

NeuroVive Pharmaceutical AB (publ) is obligated to publish the information
contained in this press release in accordance with the Swedish Securities Market
Act. This information was provided to the media for publication at 8:30 CEST on
November 18, 2015.
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, is
listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol NVP. The
share is also traded on the OTC market in the US, under the ticker symbol NEVPF